June 11, 2020 / 1:07 PM / a month ago

Emergent BioSolutions signs $87 mln deal to make AstraZeneca's COVID-19 vaccine in U.S.

June 11 (Reuters) - Emergent BioSolutions Inc said on Thursday it signed a $87 million deal to make AstraZeneca Plc’s experimental COVID-19 vaccine in the United States, as the British drugmaker looks to ramp up its efforts to bring a vaccine to the market.

Under the agreement, Emergent will help with services involving development and analytical testing and will reserve some of its large-scale manufacturing capacity through 2020 for the vaccine. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Amy Caren Daniel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below